Hill-Rom Holdings, Inc. (HRC) Shares Bought by Legal & General Group Plc
Legal & General Group Plc raised its stake in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 16.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,049 shares of the medical technology company’s stock after buying an additional 8,765 shares during the period. Legal & General Group Plc owned approximately 0.09% of Hill-Rom worth $4,592,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Seven Eight Capital LP acquired a new position in Hill-Rom during the 2nd quarter valued at about $127,000. Acrospire Investment Management LLC increased its stake in Hill-Rom by 43.4% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,983 shares of the medical technology company’s stock valued at $158,000 after buying an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Hill-Rom by 10.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after buying an additional 204 shares during the period. Citigroup Inc. increased its stake in Hill-Rom by 21.1% during the 2nd quarter. Citigroup Inc. now owns 2,483 shares of the medical technology company’s stock valued at $198,000 after buying an additional 433 shares during the period. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Hill-Rom by 101.0% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 2,720 shares of the medical technology company’s stock worth $204,000 after purchasing an additional 1,367 shares during the last quarter. 82.33% of the stock is currently owned by hedge funds and other institutional investors.
HRC has been the topic of several recent research reports. Zacks Investment Research raised shares of Hill-Rom from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. KeyCorp reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Hill-Rom in a research note on Tuesday, October 17th. ValuEngine cut shares of Hill-Rom from a “buy” rating to a “hold” rating in a research note on Saturday, November 4th. Needham & Company LLC lowered their price objective on shares of Hill-Rom from $93.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, November 6th. Finally, Stifel Nicolaus lifted their price objective on shares of Hill-Rom from $84.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $89.57.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, November 3rd. The medical technology company reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.27 by $0.05. The company had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom had a net margin of 4.87% and a return on equity of 20.27%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.18 EPS. research analysts expect that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 15th will be given a $0.18 dividend. This represents a $0.72 annualized dividend and a dividend yield of 0.84%. The ex-dividend date is Thursday, December 14th. Hill-Rom’s dividend payout ratio (DPR) is currently 36.18%.
In other news, SVP Paul Sherwood Johnson sold 1,000 shares of Hill-Rom stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now directly owns 1,066 shares of the company’s stock, valued at $88,467.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John J. Greisch sold 100,000 shares of Hill-Rom stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $82.82, for a total transaction of $8,282,000.00. Following the completion of the transaction, the chief executive officer now directly owns 230,851 shares in the company, valued at $19,119,079.82. The disclosure for this sale can be found here. Over the last three months, insiders sold 226,241 shares of company stock worth $18,708,644. 2.20% of the stock is currently owned by insiders.
Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.